Navigation Links
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea

rative colitis and Crohn's disease, and colon infections. Cosmo's first MMX(tm) product that has reached the market is LIALDA(tm) / MEZAVANT(tm), a treatment for IBD that is licensed globally to Giuliani and Shire Pharmaceuticals. Cosmo's proprietary MMX(tm) technology is at the core of the company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. For further information on Cosmo, please visit the Company's website: www.cosmopharmaceuticals.com

Contact:

Dr. Chris Tanner, CFO and Head of Investor Relations

Cosmo Pharmaceuticals SpA

Tel: +39 02 9333 7614

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

Claire Rowell Manager Financial Communications

Holborn Gate, 26 Southampton Buildings London, WC2A 1PB

T +44 (0)20 7269 7285 F +44 (0)20 7242 8695

www.fd.com

London, New York, Bahrain, Beijing, Boston, Cape Town, Chicago, Dubai, Dublin, Frankfurt, Hong Kong, Johannesburg, Manchester, Moscow, Paris, San Francisco, Stockholm and Washington.


'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: ... development and commercialization of products for central nervous ... two posters at the Society for Research on ... The first poster entitled Pleiomorphic ... provides insight into the challenges faced by ...
(Date:5/22/2012)... -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it ... and Drug Administration for its abbreviated new drug ... the generic equivalent of Gynazole·1®. Perrigo was the first ... a paragraph IV certification and is entitled to ... KV Pharmaceutical Company on a collaboration to launch ...
(Date:5/22/2012)... AUSTIN, Texas, May 22, 2012  Prodigy Generics, ... has launched injectable irinotecan. Irinotecan is the generic ... Prodigy partnered with eVenus Pharmaceutical Laboratories ... is the first of several ANDAs being developed ... and exceptional value to the U.S. injectable market, ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3Infant Organ Donors Could Help Meet Transplant Needs 3A Study 78200 1Infant Organ Donors Could Help Meet Transplant Needs 3A Study 78200 2Scripps Research chemist devises new method to quantify protein changes 17165 1Scripps Research chemist devises new method to quantify protein changes 17165 2Scripps Research chemist devises new method to quantify protein changes 17165 3Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC 1002 13706 1Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC 1002 13706 2
(Date:5/23/2012)... research suggests that young asthma patients who use drugs ... -- could be more likely than others to suffer ... increased risk was not seen for some types of ... the recent interest in use of anticholinergics in asthma," ... at Chicago, said in a news release from the ...
(Date:5/23/2012)... treatment with inhaled corticosteroids in patients with respiratory ... associated with a lower incidence and severity of ... researchers in Spain. , A parapneumonic effusion is ... accumulates between the two pleural layers, the fluid-filled ... a result of a pneumonia, lung abscess, or ...
(Date:5/22/2012)... Ill. Magnetic resonance imaging (MRI) provides an ... chemotherapy significantly earlier than possible through clinical examination, ... the journal Radiology . , Women ... surgery. Research has shown that women who receive ... likely to achieve breast conservation than those receiving ...
(Date:5/22/2012)... HealthDay Reporter , , TUESDAY, May 22 (HealthDay News) -- ... common cause of snoring and daytime sleepiness, might also ... the condition -- the risk of developing high blood ... new cases of high blood pressure in two groups ... therapy, or CPAP, for either about four or 11 ...
(Date:5/22/2012)... 22, 2012) -- Researchers at Barrow Neurological Institute ... unveiled how and why the public perceives some ... real-world implications in military tactics, marketing and sports. ... Visual Neuroscience, and Stephen Macknik, PhD, of Barrow,s ... their research into magic and illusions. Their most ...
Breaking Medicine News(10 mins):Health News:Asthma Meds May Be Linked to Irregular Heartbeat 2Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Breast MRI helps predict chemotherapy's effectiveness 2Health News:Sleep Apnea 'Mask' Might Also Help the Heart 2Health News:Sleep Apnea 'Mask' Might Also Help the Heart 3Health News:Sleep Apnea 'Mask' Might Also Help the Heart 4Health News:Barrow researchers use magic for discoveries 2
... Allergies Send 50,000 Americans to the Emergency Room Annually , ... new study from the Mayo Clinic published in the December issue ... indicates a higher incidence of anaphylactic reactions than previously reported. ... "The etiology and incidence of anaphylaxis in Rochester, Minnesota," Wyatt W. ...
... December 11, 2008 The American Cancer Society ... Terry Awards for Exemplary Leadership in Tobacco Control. The ... General Luther L. Terry, M.D., who led the landmark ... lung cancer and other illnesses. Dr. Terry,s courageous and ...
... Research Group (MRG) analyst Deanna Vankessel, author of the recently published ... report, is available to offer extensive expertise on the recent FDA ... the knee. , , MRG,s ... , , , ...
... Expected to Begin in December - , , ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: ... trial of neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. ... with advanced breast cancer positive for the ErbB-2 receptor (also known ...
... Female Health Company (NYSE Alternext: FHC) has announced that the ... Advisory Committee has unanimously voted that the company,s second-generation female ... condition. , , The ... the condition that the FC2 Female Condom,s instructions for use ...
... with ribavirin for previously untreated children with chronic hepatitis ... , KENILWORTH, N.J., Dec. 12 Schering-Plough ... the U.S. Food and Drug Administration (FDA) has granted ... USP) combination therapy for use in previously untreated patients ...
Other Medicine News:Health News:Incidence of Anaphylaxis Higher Than Previously Reported 2Health News:Incidence of Anaphylaxis Higher Than Previously Reported 3Health News:American Cancer Society recognizes international tobacco control leaders 2Health News:American Cancer Society recognizes international tobacco control leaders 3Health News:American Cancer Society recognizes international tobacco control leaders 4Health News:American Cancer Society recognizes international tobacco control leaders 5Health News:American Cancer Society recognizes international tobacco control leaders 6Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7
... CryoCath has developed a minimally ... reentrant tachycardia. It delivers a very ... site confirmation, pinpoint site precision, minimal ... thrombus and stenosis., ,Freezor Xtra allows ...
... CryoCath has developed a minimally invasive ... tachycardia. It delivers a very high ... confirmation, pinpoint site precision, minimal tissue ... and stenosis., ,Freezor is a flexible, ...
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
Ten-Ten duodecapolar diagnostic mapping catheters are available in four curve sizes....
Medicine Products: